These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19855158)

  • 21. Arctigenin suppresses receptor activator of nuclear factor κB ligand (RANKL)-mediated osteoclast differentiation in bone marrow-derived macrophages.
    Kim AR; Kim HS; Lee JM; Choi JH; Kim SN; Kim DK; Kim JH; Mun SH; Kim JW; Jeon HS; Kim YM; Choi WS
    Eur J Pharmacol; 2012 May; 682(1-3):29-36. PubMed ID: 22387094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
    Rice L; Lepler S; Pampo C; Siemann DW
    Clin Exp Metastasis; 2012 Feb; 29(2):133-42. PubMed ID: 22130962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum calcium-decreasing factor, caldecrin, inhibits osteoclast differentiation by suppression of NFATc1 activity.
    Hasegawa H; Kido S; Tomomura M; Fujimoto K; Ohi M; Kiyomura M; Kanegae H; Inaba A; Sakagami H; Tomomura A
    J Biol Chem; 2010 Aug; 285(33):25448-57. PubMed ID: 20547767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The synthetic triterpenoid TP-222 inhibits RANKL stimulation of osteoclastogenesis and matrix metalloproteinase-9 expression.
    Fava RA; Elliott S; Raymond L; Mollmark J; Hays E; Honda T; Gribble GW; Sporn MB; Vincenti MP
    J Rheumatol; 2007 May; 34(5):1058-68. PubMed ID: 17361985
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
    Merle B; Itzstein C; Delmas PD; Chenu C
    J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
    Tatarov O; Mitchell TJ; Seywright M; Leung HY; Brunton VG; Edwards J
    Clin Cancer Res; 2009 May; 15(10):3540-9. PubMed ID: 19447874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
    Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
    Chan CM; Jing X; Pike LA; Zhou Q; Lim DJ; Sams SB; Lund GS; Sharma V; Haugen BR; Schweppe RE
    Clin Cancer Res; 2012 Jul; 18(13):3580-91. PubMed ID: 22586301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoprotegerin induces podosome disassembly in osteoclasts through calcium, ERK, and p38 MAPK signaling pathways.
    Zhao H; Liu X; Zou H; Dai N; Yao L; Gao Q; Liu W; Gu J; Yuan Y; Bian J; Liu Z
    Cytokine; 2015 Feb; 71(2):199-206. PubMed ID: 25461399
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
    Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
    Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
    Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
    Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myristoleic acid inhibits osteoclast formation and bone resorption by suppressing the RANKL activation of Src and Pyk2.
    Kwon JO; Jin WJ; Kim B; Kim HH; Lee ZH
    Eur J Pharmacol; 2015 Dec; 768():189-98. PubMed ID: 26528796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth/differentiation factor-15 inhibits differentiation into osteoclasts--a novel factor involved in control of osteoclast differentiation.
    Vanhara P; Lincová E; Kozubík A; Jurdic P; Soucek K; Smarda J
    Differentiation; 2009 Nov; 78(4):213-22. PubMed ID: 19695766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
    Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
    J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate cancer promotes CD11b positive cells to differentiate into osteoclasts.
    Mizutani K; Sud S; Pienta KJ
    J Cell Biochem; 2009 Mar; 106(4):563-9. PubMed ID: 19170075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo.
    Goc A; Al-Husein B; Katsanevas K; Steinbach A; Lou U; Sabbineni H; DeRemer DL; Somanath PR
    Oncotarget; 2014 Feb; 5(3):775-87. PubMed ID: 24519956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Src controls castration recurrence of CWR22 prostate cancer xenografts.
    Su B; Gillard B; Gao L; Eng KH; Gelman IH
    Cancer Med; 2013 Dec; 2(6):784-92. PubMed ID: 24403252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of p38 mitogen-activated protein kinase is crucial in osteoclastogenesis induced by tumor necrosis factor.
    Matsumoto M; Sudo T; Maruyama M; Osada H; Tsujimoto M
    FEBS Lett; 2000 Dec; 486(1):23-8. PubMed ID: 11108836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.